These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31602769)

  • 21. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world experience with reversal of dabigatran by idarucizumab.
    Haastrup SB; Hellfritzsch M; Nybo M; Hvas AM; Grove EL
    Thromb Res; 2021 Jan; 197():179-184. PubMed ID: 33227654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.
    Stone L; Merriman E; Hanna M; Royle G; Chan H
    Thromb Haemost; 2022 Jul; 122(7):1096-1103. PubMed ID: 34814227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
    Levy JH; van Ryn J; Sellke FW; Reilly PA; Elsaesser A; Glund S; Kreuzer J; Weitz JI; Pollack CV
    Ann Surg; 2021 Sep; 274(3):e204-e211. PubMed ID: 31599808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The first experience with dabigatran antidote in the University Hospital Pilsen].
    Šlechtová J; Hajšmanová Z; Lavičková A; Šigutová P
    Cas Lek Cesk; 2016; 155(8):442-444. PubMed ID: 28098476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
    Rosenberg L; Gerstrøm G; Nybo M
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.
    Pikija S; Sztriha LK; Sebastian Mutzenbach J; Golaszewski SM; Sellner J
    CNS Drugs; 2017 Sep; 31(9):747-757. PubMed ID: 28808918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
    Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
    J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit: A case report.
    Thirunavukkarasu S; Kalashyan H; Jickling G; Jeerakathil TJ; Jayaprakash HK; Buck BH; Shuaib A; Butcher K
    Medicine (Baltimore); 2020 May; 99(21):e20200. PubMed ID: 32481289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran.
    Calabria S; Forcesi E; Dondi L; Pedrini A; Maggioni AP; Martini N
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):281-286. PubMed ID: 29869189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients.
    Elalamy I; Crisan O; Gruenenfelder F; Benarousse G; Tazarourte K
    Eur J Emerg Med; 2019 Jun; 26(3):230-231. PubMed ID: 31033622
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.